Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma

NICE technology appraisals [TA178] Published date:

Bevacizumab, sorafenib and temsirolimus are not recommended as first drug treatments for people with advanced and/or metastatic renal cell carcinoma.

Sorafenib and sunitinib are not recommended as second drug treatments for people with advanced and/or metastatic renal cell carcinoma.

Specialists should not stop prescribing bevacizumab, sorafenib, sunitinib and temsirolimus for people who were already taking them when the guidance was issued. These people should be able to carry on taking bevacizumab, sorafenib, sunitinib and temsirolimus until they and their specialists decide that it is the right time to stop treatment.

Get involved